Rice Hall James & Associates LLC Has $4.04 Million Stock Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Rice Hall James & Associates LLC trimmed its holdings in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) by 73.1% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 268,337 shares of the company’s stock after selling 730,288 shares during the quarter. Rice Hall James & Associates LLC’s holdings in Pacira BioSciences were worth $4,038,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. increased its position in Pacira BioSciences by 62.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 8,872 shares of the company’s stock worth $134,000 after buying an additional 3,404 shares during the last quarter. Assenagon Asset Management S.A. increased its position in Pacira BioSciences by 314.4% during the third quarter. Assenagon Asset Management S.A. now owns 553,114 shares of the company’s stock worth $8,324,000 after buying an additional 419,656 shares during the last quarter. Hennion & Walsh Asset Management Inc. increased its position in Pacira BioSciences by 34.7% during the third quarter. Hennion & Walsh Asset Management Inc. now owns 47,749 shares of the company’s stock worth $719,000 after buying an additional 12,299 shares during the last quarter. Allspring Global Investments Holdings LLC increased its position in Pacira BioSciences by 1,398.8% during the third quarter. Allspring Global Investments Holdings LLC now owns 100,181 shares of the company’s stock worth $1,508,000 after buying an additional 93,497 shares during the last quarter. Finally, Wedge Capital Management L L P NC increased its position in Pacira BioSciences by 131.9% during the third quarter. Wedge Capital Management L L P NC now owns 119,447 shares of the company’s stock worth $1,798,000 after buying an additional 67,947 shares during the last quarter. 99.73% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Pacira BioSciences news, CEO Frank D. Lee purchased 8,264 shares of the business’s stock in a transaction on Monday, August 12th. The stock was purchased at an average price of $12.10 per share, for a total transaction of $99,994.40. Following the completion of the purchase, the chief executive officer now directly owns 107,784 shares in the company, valued at approximately $1,304,186.40. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders acquired a total of 11,176 shares of company stock worth $136,240 over the last quarter. Company insiders own 6.40% of the company’s stock.

Pacira BioSciences Stock Down 1.6 %

Shares of PCRX opened at $16.60 on Friday. The stock has a market cap of $765.76 million, a price-to-earnings ratio of 12.67 and a beta of 0.84. The company has a quick ratio of 5.70, a current ratio of 6.82 and a debt-to-equity ratio of 0.67. Pacira BioSciences, Inc. has a 12 month low of $11.16 and a 12 month high of $35.95. The company has a 50-day moving average price of $15.34 and a two-hundred day moving average price of $21.39.

Pacira BioSciences (NASDAQ:PCRX) last announced its quarterly earnings results on Tuesday, July 30th. The company reported $0.64 EPS for the quarter, topping analysts’ consensus estimates of $0.53 by $0.11. The firm had revenue of $178.02 million during the quarter, compared to analysts’ expectations of $173.31 million. Pacira BioSciences had a net margin of 9.21% and a return on equity of 13.22%. Equities analysts predict that Pacira BioSciences, Inc. will post 2.2 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on PCRX. Piper Sandler downgraded Pacira BioSciences from an “overweight” rating to a “neutral” rating and lowered their price target for the company from $42.00 to $11.00 in a research report on Monday, August 12th. Needham & Company LLC lowered their price target on Pacira BioSciences from $43.00 to $22.00 and set a “buy” rating on the stock in a research report on Monday, August 12th. StockNews.com downgraded Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a research report on Monday, August 12th. Royal Bank of Canada raised their price target on Pacira BioSciences from $14.00 to $15.00 and gave the company a “sector perform” rating in a research report on Friday, October 4th. Finally, Raymond James downgraded Pacira BioSciences from an “outperform” rating to a “market perform” rating in a research report on Monday, August 12th. Two analysts have rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, Pacira BioSciences currently has a consensus rating of “Hold” and a consensus target price of $24.20.

Pacira BioSciences Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.